Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Efficacy and Safety of Bevacizumab Combined With Double Doses of Icotinib in Advanced Non-squamous Non-small Cell Lung Cancer With EGFR Exon 21 L858R Mutation: a Prospective, Single-arm, Phase 2 Clinical Trial
Tianjin Medical University Cancer Institute and Hospital